Therapeutic Management of Hyperlipoproteinemia (a)

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2019 Sep 27

PMID 31555339

Citations 10

Authors

Constantine E Kosmas

Andreas Sourlas

Gordon Mallarkey

Delia Silverio

Domingo Y Ynoa

Peter D Montan

Eliscer Guzman

Mario J Garcia

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as well as calcific aortic valve stenosis. Thus, the therapeutic management of hyperlipoproteinemia (a) has received much attention, as significant reductions in Lp(a) levels may, potentially, favorably affect cardiovascular risk. Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). This review aims to present and discuss the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).

Citing Articles

Lipids dysregulation in diseases: core concepts, targets and treatment strategies.

Dakal T, Xiao F, Bhusal C, Sabapathy P, Segal R, Chen J Lipids Health Dis. 2025; 24(1):61.

PMID: 39984909 PMC: 11843775. DOI: 10.1186/s12944-024-02425-1.

Lipoprotein (a) and cerebrovascular disease.

Kosmas C, Bousvarou M, Papakonstantinou E, Zoumi E, Rallidis L J Int Med Res. 2024; 52(7):3000605241264182.

PMID: 39082245 PMC: 11295242. DOI: 10.1177/03000605241264182.

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.

Sosnowska B, Stepinska J, Mitkowski P, Bielecka-Dabrowa A, Bobrowska B, Budzianowski J Arch Med Sci. 2024; 20(1):8-27.

PMID: 38414479 PMC: 10895977. DOI: 10.5114/aoms/183522.

Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization.

Chang Y, Hsu L, Ko Y Int J Mol Sci. 2023; 24(19).

PMID: 37834124 PMC: 10572552. DOI: 10.3390/ijms241914668.

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a).

Kosmas C, Bousvarou M, Papakonstantinou E, Tsamoulis D, Koulopoulos A, Echavarria Uceta R Int J Mol Sci. 2023; 24(17).

PMID: 37686428 PMC: 10487774. DOI: 10.3390/ijms241713622.

References

Mendelsohn M, Karas R . The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999; 340(23):1801-11. DOI: 10.1056/NEJM199906103402306. View

Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T . Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem. 1999; 274(48):34111-5. DOI: 10.1074/jbc.274.48.34111. View

Shlipak M, Simon J, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000; 283(14):1845-52. DOI: 10.1001/jama.283.14.1845. View

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K . Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002; 48(9):1454-9. View

Vane J, Botting R . The mechanism of action of aspirin. Thromb Res. 2003; 110(5-6):255-8. DOI: 10.1016/s0049-3848(03)00379-7. View

Birjmohun R, Hutten B, Kastelein J, Stroes E . Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005; 45(2):185-97. DOI: 10.1016/j.jacc.2004.10.031. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Salpeter S, Walsh J, Ormiston T, Greyber E, Buckley N, Salpeter E . Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006; 8(5):538-54. DOI: 10.1111/j.1463-1326.2005.00545.x. View

10.

Qian Y, Schmidt R, Zhang Y, Chu S, Lin A, Wang H . Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007; 48(7):1488-98. DOI: 10.1194/jlr.M700071-JLR200. View

11.

Sofi F, Marcucci R, Abbate R, Gensini G, Prisco D . Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med. 2007; 120(8):728-33. DOI: 10.1016/j.amjmed.2007.01.029. View

12.

Ranga G, Kalra O, Tandon H, Gambhir J, Mehrotra G . Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2007; 16(5):220-4. DOI: 10.1016/j.jstrokecerebrovasdis.2007.05.003. View

13.

Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M . Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008; 168(6):598-608. DOI: 10.1001/archinte.168.6.598. View

14.

Danik J, Rifai N, Buring J, Ridker P . Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008; 52(2):124-31. PMC: 2958092. DOI: 10.1016/j.jacc.2008.04.009. View

15.

Chasman D, Shiffman D, Zee R, Louie J, Luke M, Rowland C . Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2008; 203(2):371-6. PMC: 2678922. DOI: 10.1016/j.atherosclerosis.2008.07.019. View

16.

Tziomalos K, Athyros V, Wierzbicki A, Mikhailidis D . Lipoprotein a: where are we now?. Curr Opin Cardiol. 2009; 24(4):351-7. DOI: 10.1097/HCO.0b013e32832ac21a. View

17.

Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White I . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302(4):412-23. PMC: 3272390. DOI: 10.1001/jama.2009.1063. View

18.

Ladenson P, Kristensen J, Chester Ridgway E, Olsson A, Carlsson B, Klein I . Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362(10):906-16. DOI: 10.1056/NEJMoa0905633. View

19.

Sangkuhl K, Shuldiner A, Klein T, Altman R . Platelet aggregation pathway. Pharmacogenet Genomics. 2010; 21(8):516-21. PMC: 3134593. DOI: 10.1097/FPC.0b013e3283406323. View

20.

Cannon C, Shah S, Dansky H, Davidson M, Brinton E, Gotto A . Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010; 363(25):2406-15. DOI: 10.1056/NEJMoa1009744. View